One of the major complications by metabolic syndrome is chronic kidney disease (CKD). 37 million American adults have CKD and millions of others are at increased risk.
Current medicines cannot reverse CKD. RB394 can potentially become the first treatment available as it demonstrates efficacy against CKD by reducing renal inflammation, oxidative stress, tubular injury, and vascular injury.
Two main causes of chronic kidney disease are diabetes and high blood pressure, which are often associated with metabolic syndrome.